Retrophin (RTRX) Rating Lowered to Sell at ValuEngine

ValuEngine cut shares of Retrophin (NASDAQ:RTRX) from a hold rating to a sell rating in a research report report published on Saturday.

Several other equities analysts have also weighed in on RTRX. BidaskClub upgraded shares of Retrophin from a hold rating to a buy rating in a report on Wednesday, January 10th. BMO Capital Markets restated a buy rating and issued a $44.00 price objective on shares of Retrophin in a report on Friday, October 6th. Finally, Zacks Investment Research lowered shares of Retrophin from a hold rating to a sell rating in a report on Thursday, January 11th. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating and two have given a buy rating to the company’s stock. Retrophin presently has a consensus rating of Hold and an average price target of $44.00.

Shares of Retrophin (NASDAQ RTRX) traded down $1.07 during midday trading on Friday, reaching $22.79. 224,930 shares of the company traded hands, compared to its average volume of 203,216. Retrophin has a fifty-two week low of $15.55 and a fifty-two week high of $26.44. The firm has a market capitalization of $874.80, a price-to-earnings ratio of -17.27 and a beta of 1.26. The company has a debt-to-equity ratio of 0.15, a current ratio of 3.88 and a quick ratio of 3.83.

Retrophin (NASDAQ:RTRX) last announced its quarterly earnings data on Tuesday, November 7th. The biopharmaceutical company reported ($0.46) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.25) by ($0.21). Retrophin had a negative net margin of 33.79% and a negative return on equity of 10.13%. The business had revenue of $40.34 million during the quarter, compared to analyst estimates of $40.51 million. During the same quarter in the prior year, the company earned ($0.09) earnings per share. The company’s quarterly revenue was up 18.8% on a year-over-year basis. equities research analysts anticipate that Retrophin will post -1.24 earnings per share for the current fiscal year.

A number of large investors have recently modified their holdings of the business. Perceptive Advisors LLC increased its stake in Retrophin by 0.5% in the third quarter. Perceptive Advisors LLC now owns 2,686,204 shares of the biopharmaceutical company’s stock valued at $66,859,000 after purchasing an additional 13,895 shares in the last quarter. Vanguard Group Inc. increased its stake in Retrophin by 8.3% in the second quarter. Vanguard Group Inc. now owns 1,635,234 shares of the biopharmaceutical company’s stock valued at $31,707,000 after purchasing an additional 125,695 shares in the last quarter. Macquarie Group Ltd. increased its stake in Retrophin by 22.7% in the third quarter. Macquarie Group Ltd. now owns 1,459,218 shares of the biopharmaceutical company’s stock valued at $36,320,000 after purchasing an additional 270,399 shares in the last quarter. Dimensional Fund Advisors LP increased its stake in Retrophin by 8.7% in the third quarter. Dimensional Fund Advisors LP now owns 896,815 shares of the biopharmaceutical company’s stock valued at $22,322,000 after purchasing an additional 71,562 shares in the last quarter. Finally, Northern Trust Corp increased its stake in Retrophin by 3.8% in the second quarter. Northern Trust Corp now owns 708,248 shares of the biopharmaceutical company’s stock valued at $13,732,000 after purchasing an additional 26,119 shares in the last quarter.

TRADEMARK VIOLATION NOTICE: This article was posted by Community Financial News and is the property of of Community Financial News. If you are reading this article on another site, it was illegally copied and republished in violation of U.S. and international copyright & trademark laws. The original version of this article can be viewed at https://www.com-unik.info/2018/02/04/retrophin-rtrx-rating-lowered-to-sell-at-valuengine.html.

About Retrophin

Retrophin, Inc is a biopharmaceutical company. The Company is focused on the development, acquisition and commercialization of therapies for the treatment of serious, catastrophic or rare diseases. The Company sells three products, including Chenodal (chenodeoxycholic acid), Cholbam (cholic acid) and Thiola (tiopronin).

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Retrophin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Retrophin and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit